Combination therapy with metformin and fenofibrate for insulin resistance in obesity

Journal of International Medical Research

Volumn 39, Issue 5, 2011, Pages 1876-1882

  Li, X M ^a   Li, Y ^a   Zhang, N N ^a   Xie, Y H ^a   Shi, Y Q ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Fenofibrate; Insulin Resistance; Metformin; Obesity; Oral Hypoglycaemic Agent; PPAR Agonist; Cell Function

Indexed keywords

FATTY ACID; FENOFIBRATE; INSULIN; LIPID; METFORMIN; PLACEBO;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA AND VOMITING; OBESITY; PANCREAS ISLET CELL FUNCTION; RANDOMIZED CONTROLLED TRIAL;

EID: 80155212616     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900531     Document Type: Article

References (31)

1. DeFronzo RA, Del Prato S: Insulin resistance and diabetes mellitus. J Diabetes Complications 1996; 10: 243-245.
2. Watson KE, Horowitz BN, Matson G: Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med 2003; 4: 228-236.
3. Poitout V, Robertson RP: Minireview: secondary 3-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-342.
4. Imrie H, Abbas A, Kearney M: Insulin resistance, lipotoxicity and endothelial dysfunction. Biochim Biophys Acta 2010; 1801: 320-326.
5. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
6. Kay JP, Alemzadeh R, Langley G, et al: Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50: 1457-1461.
7. Freemark M, Bursey D: The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107: E55.
8. Landin K, Tengborn L, Smith U: Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic euglycemic clamp in man. Thromb Haemost 1994; 71: 783-787.
9. Fendri S, Roussel B, Lormeau B, et al: Insulin sensitivity, insulin action and fibrinolysis activity in non-diabetic and diabetic obese subjects. Metabolism 1998; 47: 1372-1375.
10. Chinese Ministry of Health Disease Control Division: Chinese Prevention and Control Guidelines for Overweight and Obese Adults (Trial). Beijing: Chinese Ministry of Health, 2003; pp 3-5 [in Chinese].
11. Willig SH: Good Manufacturing Practice Guidelines for Pharmaceuticals. Abingdon: Taylor and Francis, 2005.
12. Trinder P: Determination of blood glucose using an oxidase-peroxidase system with a noncarcinogenic chromogen. J Clin Pathol 1969; 22: 158-161.
13. Tuan C-Y, Abbasi F, Lamendola C, et al: Usefulness of plasma glucose and insulin concentrations in identifying patients with insulin resistance. Am J Cardiol 2003; 92: 606-610.
14. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
15. Puttmann M, Krug H, von Ochsenstein E, et al: Fast HPLC determination of serum free fatty acids in the picomole range. Clin Chem 1993; 39: 825-832.
16. Swislocki AL, Chen YD, Golay A, et al: Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (non-insulin-dependent) diabetes. Diabetologia 1987; 30: 622-626.
17. Makowski L, Hotamisligil GS: The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 2005; 16: 543-548.
18. Maeda K, Cao H, Kono K, et al: Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005; 1: 107-119.
19. Steinberg HO, Chaker H, Leaming R, et al: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610.
20. Rizzo M, Kotur-Stevuljevic J, Berneis K, et al: Atherogenic dyslipidemia and oxidative stress: a new look. Transl Res 2009; 153: 217-223.
21. Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med 2002 137: 25-33.
22. Kliewer SA, Xu HE, Lambert MH, et al: Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 2001; 56: 239-263.
23. Grundy SM, Vega GL: Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987; 83: 9-20.
24. Effect of fenofibrate on progression of coronaryartery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910.
25. Anderlová K, Dolezalová R, Housová J, et al: Influence of PPAR-nnagonist fenofibrate on insulin sensitivity and selected adipose tissuederived hormones in obese women with type 2 diabetes. Physiol Res 2007; 56: 579-586.
26. Poli KA, Tofler GH, Larson MG, et al: Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101: 264-269.
27. Westerbacka J, Vehkavaara S, Bergholm R, et al: Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes 1999; 48: 821-827.
28. James PT, Leach R, Kalamara E, et al: The worldwide obesity epidemic. Obes Res 2001; 9(suppl 4): 228S-233S.
29. Shimabukuro M, Zhou YT, Levi M, et al: Fatty acid-induced a-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998; 95: 2498-2502.
30. Domanski MJ, Jablonski KA: Obesity and cardiovascular events in patients with established coronary disease. Eur Heart J 2006; 27: 1416-1422.
31. Booth GL, Kapral MK, Fung K, et al: Relation between age and cardiovascular disease in men and women with diabetes compared with nondiabetic people: a population-based retrospective cohort study. Lancet 2006; 368: 29-36.